Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vasopeptidase inhibitors.

Giuseppe A Sagnella1

  • 1Blood Pressure Unit, St Georges Hospital Medical School, London, UK. g.sagnella@sghms.ac.uk

Journal of the Renin-Angiotensin-Aldosterone System : JRAAS
|September 14, 2002
PubMed
Summary

New vasopeptidase inhibitors offer dual action, blocking angiotensin II and boosting natriuretic peptides. These drugs show promise for treating hypertension and congestive heart failure (CHF).

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Plasma aldosterone: comparison of a new automated assay with a standard extraction method.

Clinical chemistry·2006
Same author

Modest salt reduction reduces blood pressure and urine protein excretion in black hypertensives: a randomized control trial.

Hypertension (Dallas, Tex. : 1979)·2005
Same author

Circulating soluble E-selectin levels and the Ser 128Arg polymorphism in individuals from different ethnic groups.

Nutrition, metabolism, and cardiovascular diseases : NMCD·2005
Same author

Plasma sodium: ignored and underestimated.

Hypertension (Dallas, Tex. : 1979)·2004
Same author

Direct renin assay and plasma renin activity assay compared.

Clinical chemistry·2004
Same author

Molecular variants of the sodium/hydrogen exchanger type 3 gene and essential hypertension.

Journal of hypertension·2004

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Nephrology

Background:

  • Vasopeptidase inhibitors target two key enzymes in vasoactive peptide metabolism.
  • They inhibit angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP).
  • This dual action reduces angiotensin II and increases natriuretic peptides.

Purpose of the Study:

  • To explore the therapeutic potential of vasopeptidase inhibitors.
  • To evaluate their efficacy in cardiovascular and renal diseases, particularly hypertension and congestive heart failure (CHF).

Main Methods:

  • Clinical investigations and trials of several vasopeptidase inhibitors, including omapatrilat.
  • Assessment of antihypertensive activity across diverse patient populations.
  • Evaluation of treatment potential for CHF and ischemic heart disease.

Main Results:

  • Demonstrated effective antihypertensive activity, irrespective of age, renin, salt status, or ethnicity.
  • Highlighted potential as a new therapeutic approach for congestive heart failure (CHF).

Conclusions:

  • Vasopeptidase inhibitors represent a novel therapeutic class with significant potential.
  • They offer advantages for treating hypertension, CHF, and potentially ischemic heart disease.

Related Experiment Videos